HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-κB p65 transcriptional activity  by Leus, Niek G.J. et al.
Biochemical Pharmacology 108 (2016) 58–74Contents lists available at ScienceDirect
Biochemical Pharmacology
journal homepage: www.elsevier .com/locate /b iochempharmHDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory
properties in RAW 264.7 macrophages and mouse precision-cut lung
slices by attenuating NF-jB p65 transcriptional activityhttp://dx.doi.org/10.1016/j.bcp.2016.03.010
0006-2952/ 2016 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
⇑ Corresponding author.
E-mail address: f.j.dekker@rug.nl (F.J. Dekker).Niek G.J. Leus a, Petra E. van der Wouden a, Thea van den Bosch a, Wouter T.R. Hooghiemstra a,
Maria E. Ourailidou a, Loes E.M. Kistemaker c, Rainer Bischoff b, Reinoud Gosens c, Hidde J. Haisma a,
Frank J. Dekker a,⇑
aDepartment of Pharmaceutical Gene Modulation, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The
Netherlands
bDepartment of Analytical Biochemistry, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
cDepartment of Molecular Pharmacology, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
a r t i c l e i n f o a b s t r a c tArticle history:
Received 14 January 2016
Accepted 14 March 2016
Available online 16 March 2016
Chemical compounds studied in this article:
RGFP966 (PubChem CID: 56650312)
N,N-Dimethylformamide (PubChem CID:
6228)
Suberoylanilide hydroxamic acid (PubChem
CID: 5311)
Keywords:
Lysine acetylation
HDACs
Inflammation
NF-jB p65
HDAC inhibitors
Lung diseaseThe increasing number of patients suffering from chronic obstructive pulmonary disease (COPD) repre-
sents a major and increasing health problem. Therefore, novel therapeutic approaches are needed.
Class I HDACs 1, 2 and 3 play key roles in the regulation of inflammatory gene expression with a
particular pro-inflammatory role for HDAC 3. HDAC 3 has been reported to be an important player in
inflammation by deacetylating NF-jB p65, which has been implicated in the pathology of COPD. Here,
we applied the pharmacological HDAC 3-selective inhibitor RGFP966, which attenuated pro-
inflammatory gene expression in models for inflammatory lung diseases. Consistent with this, a robust
decrease of the transcriptional activity of NF-jB p65 was observed. HDAC 3 inhibition affected neither
the acetylation status of NF-jB p65 nor histone H3 or histone H4. This indicates that HDAC 3 inhibition
does not inhibit NF-jB p65 transcriptional activity by affecting its deacetylation but rather by inhibiting
enzymatic activity of HDAC 3. Taken together, our findings indicate that pharmacological HDAC
3-selective inhibition by inhibitors such as RGFP966 may provide a novel and effective approach toward
development of therapeutics for inflammatory lung diseases.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic obstructive pulmonary disease (COPD) is a major and
increasing health problem that is a leading cause of death world-
wide [1]. COPD is associated with chronic inflammatory responses,
predominantly in small airways and lung parenchyma. For some
patients the currently available anti-inflammatory therapy is not
effective due to reduced responsiveness to corticosteroids [2]. Con-
sidering this, it is necessary to explore molecular mechanisms that
influence inflammatory responses within the context of lung
inflammation with the perspective to develop novel therapeutics.Gene expression in inflammatory signaling is among others
regulated by post-translational modifications of histone proteins,
for example lysine acetylations. The enzymes regulating the
balance between lysine acetylation and deacetylation are denoted
as histone acetyltransferases (HATs) and histone deacetylases
(HDACs), respectively [3–5]. Aberrant activities of either HATs or
HDACs alter the expression of (disease-associated) genes and con-
tribute to the development of diseases like cancer and chronic
inflammation [6,7], also including COPD.
Apart from histones also non-histone proteins, like the NF-jB
p65 transcription factor, which has been implicated in the pathol-
ogy of COPD, are modified by histone-modifying enzymes such as
HDACs [8]. Acetylations of specific lysine residues in NF-jB p65
play a key role in the regulation of its transcriptional capacity,
DNA binding ability and duration of action resulting in NF-jB
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jB p65 have been described to be subjected to acetylation, respec-
tively, 122, 123, 218, 221, 310, 314 and 315. Acetylations at lysines
122 and 123 decrease DNA binding, whereas acetylations at lysines
218 and 221 increase binding to jB enhancers. While acetylation
at lysine 310 is required for full transcriptional activity of NF-jB
p65, it does not affect DNA binding or assembly with IjBa [12].
Acetylations at lysines 314 and 315 do not affect the general
transcriptional activity of the NF-jB complex, but rather increase
promoter selectivity [13]. These examples demonstrate that direct
acetylation or deacetylation of specific lysine residues of NF-jB
p65 plays a crucial role in the regulation of NF-jB-mediated gene
expression.
Several studies have shed more light on the role of HDAC iso-
enzymes in the NF-jB p65 pathway, notably HDAC 3. HDAC 3
has been reported to be an important player in inflammation by
deacetylating NF-jB p65. For example, the positive regulatory role
of HDAC 3 in IL-1-induced (human IL-8 or murine Cxcl2) gene
expression involves binding to the NF-jB p65 subunit and con-
comitant deacetylation at various lysines [14]. In the same study,
using mutagenesis it was demonstrated that acetylation at lysine
314 and 315, in addition to acetylation at lysine 122 and 123, neg-
atively regulates NF-jB p65 activity. Moreover, it was shown that
HDAC 3 is involved in the removal of the inhibitory NF-jB p65
acetylations at lysine 122, 123, 314 and 315. Therefore, HDAC 3
is an important positive regulator in IL-1-induced inflammatory
signaling by deacetylating four specific lysines in the NF-jB p65
subunit.
Considering the importance of HDAC 3 in the NF-jB pathway,
small molecules interfering with the enzymatic activity of HDAC
3 have great potential to regulate the acetylation and so the activ-
ity of NF-jB p65 thereby affecting inflammatory gene expression.
Very recently a possible role has been described for HDAC 3 in
LPS-mediated pulmonary endothelial barrier dysfunction and
acute lung injury [15] indicating that HDAC 3-selective inhibition
may in particular have potential as anti-inflammatory therapy in
inflammatory lung diseases.
Ongoing efforts to develop HDAC inhibitors with improved
selectivity provided the inhibitor RGFP966 [16], a selective and
potent inhibitor of HDAC 3 with nanomolar potency and no
effective inhibition of any other class I HDAC at low micromolar
concentrations [17–19]. The development of this potent and
HDAC-3-selective inhibitor sets the stage to explore this inhibitor
in inflammatory diseases. Based on current literature on the acti-
vating role of HDAC 3 in pro-inflammatory gene expression via
the NF-jB pathway, we hypothesize that selective pharmacological
inhibition of HDAC 3 would inhibit pro-inflammatory gene expres-
sion in model systems for inflammatory lung diseases by inhibition
of the activation of the NF-jB pathway.
In this study we explored the utility of the HDAC 3 inhibitor
RGFP966 to alter the balance between pro- and anti-
inflammatory gene expression in in vitro and ex vivo models for
inflammatory lung diseases. Firstly, we investigated the effects of
siRNA-mediated downregulation of HDACs 1, 2 and 3 on inflamma-
tory gene expression in mouse RAW 264.7 macrophages. Next, we
examined the effects of RGFP966 on attenuating inflammatory
gene expression in cell-based model systems for inflammatory
lung diseases using mouse RAW 264.7 macrophages, human bron-
chial epithelial (HBE) cells and human airway smooth muscle
(hASM) cells. Subsequently, ex vivo cultured mouse precision-cut
lung slices (PCLS) were subjected to HDAC 3 inhibition by
RGFP966. In RAW 264.7 macrophages and mouse PCLS, RGFP966
robustly downregulated pro-inflammatory and upregulated
anti-inflammatory gene expression. The mechanism of action
of RGFP966 was further investigated in mouse RAW 264.7
macrophages with respect to NF-jB p65 transcriptional activity,inhibition of NF-jB p65 and histone acetylation, and intracellular
localization of NF-jB p65 and HDACs 1–3.2. Methods and materials
2.1. Cell culture
Mouse RAW 264.7 macrophages were obtained from the Amer-
ican Type Culture Collection (ATCC; Wesel, Germany) and cultured
in plastic tissue culture plates or flasks (Costar Europe, Badhoeve-
dorp, The Netherlands) at 37 C under 5% CO2/95% air in Dulbecco’s
Modification of Eagle’s Medium (DMEM) containing GlutaMAXTM
(Gibco by Life Technologies, Bleiswijk, The Netherlands) supple-
mented with 10% (v/v) heat inactivated fetal bovine serum (FBS;
Invitrogen, Breda, The Netherlands), 2 mM additional GlutaMAXTM
(Gibco by Life Technologies), 100 U/ml penicillin (Gibco by Life
Technologies) and 100 lg/ml streptomycin (Gibco by Life Tech-
nologies). RAW 264.7 macrophages were used between passage 5
and 16.
The immortalized human bronchial epithelial cell line
(16HBE14o-; abbreviated as HBE) was kindly provided by Dr. D.C.
Gruenert, University of Vermont, Burlington, Vermont, USA [20].
Cells were cultured in fibronectin/collagen-coated plastic tissue
culture plates or flasks at 37 C under 5% CO2/95% air in minimal
essential medium (MEM) supplemented with 10% heat inactivated
FBS, 2 mM L-glutamine (Gibco by Life Technologies), 50 U/ml
penicillin and 50 lg/ml streptomycin, as described previously
[21]. HBE cells were used between passage 73 and 103. Cells were
serum-starved in MEM supplemented with antibiotics prior to
each experiment.
Human airway smooth muscle (hASM) cell lines, immortalized
by human telomerase reverse transcriptase were kindly provided
by Prof. Dr. R. Gosens (Department of Molecular Pharmacology,
University of Groningen). The primary cultured hASM cells used
to generate each immortalized cell line were prepared as described
previously [22]. hASM cells were cultured in plastic tissue culture
plates or flasks at 37 C under 5% CO2/95% air in DMEM supple-
mented with 10% FBS, 50 U/ml penicillin and 50 lg/ml strepto-
mycin. For all experiments, immortalized hASM cells derived
from two to three different donors were used between passage
27 and 35. Prior to experimentation, cells were serum-starved in
DMEM supplemented with antibiotics and ITS (5 lg/ml insulin,
5 lg/ml transferrin and 5 ng/ml selenium).2.2. HDAC 1–3 downregulation by siRNA
In order to downregulate the expression of HDACs 1, 2 and 3,
cells were subjected to HDAC 1–3 selective siRNAs as follows.
One day prior to transfection, RAW 264.7 macrophages were
seeded at 20,000 cells/cm2 to obtain identical cell density at the
start of the experiment. siRNA transfection experiments were per-
formed in a 12-well plate upon complexing 50 nM siRNA with
3.5 ll Lipofectamine 2000 (LF2K, Life technologies) according to
the manufacturer’s protocol. After 24 h RAW 264.7 macrophages
were washed twice with ice-cold PBS and harvested for RNA isola-
tion or Western blotting. Where indicated, cells were stimulated
with 10 ng/ml lipopolysaccharide (LPS, Escherichia coli, serotype
0111:B4; Sigma–Aldrich, Zwijndrecht, The Netherlands) and
10 ng/ml interferon gamma (IFNc, #315-05; PeproTech, Hamburg,
Germany) for the last 4 h of the experiment. The following siRNAs
were used: mouse HDAC 1 (s119559), HDAC 2 (s67417), HDAC 3
(s67421) and Negative Control siRNA (4390843). All siRNAs used
were Silencer Select Pre-Designed & Validated siRNAs purchased
from Ambion by Life Technologies.
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RAW264.7macrophages, human bronchial epithelial (HBE) cells
and human airway smooth muscle (hASM) cells were incubated
with 0.41 lM SAHA, 1 lM RGFP966 (RAW 264.7) or 2 lM RGFP966
(HBE and hASM) for 20 h and stimulated with LPS/IFNc for the last
4 h of the experiment. Subsequently, cells were washed twice with
ice-cold Dulbecco’s Phosphate-buffered Saline (DPBS; Gibco by
Life Technologies) and total RNA was isolated using the SV Total
RNA Isolation kit (Promega, Leiden, The Netherlands). RNA from
mouse precision-cut lung slices (PCLS) was isolated using the Max-
well 16 LEV simplyRNA Tissue Kit (Promega). Both RNA isolation
procedures were performed according to the manufacturer’s proto-
col. RNA integrity was determined by 28S/18S ratio detection on an
1% agarose gel, which was consistently found intact. RNA concen-
tration (OD260) and purity (OD260/OD280) were measured by
NanoDrop ND-1000 UV–Vis spectrophotometer (NanoDrop Tech-
nologies, Wilmington, DE, USA). For gene expression analysis,
RNA was reverse transcribed using the Reverse Transcription kit
(#A3500, Promega). Subsequently, 10 ng of cDNA was applied for
each RT-qPCR, which was performed on an ABI Prism 7900HT
Sequence Detection System (Applied Biosystems, Nieuwerkerk a/d
IJssel, The Netherlands). The primers for TNFa (Mm00443258_m1
and Hs01113624_g1), iNOS (Mm00440502_m1 and Hs01075529_
m1), IL-1b (Mm00434228_m1 and Hs01555410_m1), IL-6
(Mm00446190_m1 and Hs00985639_m1), IL-10 (Mm00439614_m1
and Hs00961622_m1), IL-12b (Mm00434174_m1 and Hs01011518_
m1), HDAC 1 (Mm02391771_g1), HDAC 2 (Mm00515108_m1),
HDAC 3 (Mm00515916_m1), Arg1 (Mm00475988_m1), Fizz1
(Mm00445109_m1), MRC1 (Mm00485148_m1) and GAPDH
(Mm99999915_g1 and Hs02758991_g1) were purchased as Assay-
on-Demand (Applied Biosystems). For each sample, the real-time
PCR reactions were performed in duplicate and the averages of the
obtained Ct values were used for further calculations. Data analysis
was performed with the relative quantification manager software
(Applied Biosystems). Gene expression levels were normalized to
the expression of the reference gene glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), which was not influenced by the experi-
mental conditions resulting in the DCt value. Gene expression levels
were calculated by the comparative Ct method (2DDCt) [23].
2.4. Protein expression analysis by Western blot
RAW 264.7 macrophages were washed twice with ice-cold
DPBS and subsequently lysed in ice-cold cell lysis buffer (25 mM
Hepes, 5 mMMgCl2, 5 mM EDTA, 0.5% Triton X-100; supplemented
with 1 mM DTT, 1 mM sodium butyrate, and protease inhibitors
(#88266; Thermo Scientific, Rockford, IL, USA)). Next, lysates were
freeze-thawed (4) and centrifuged (10 min, 13,000g) to remove
cell debris. Protein concentrations were determined using the RC
DC Protein Assay (Bio-Rad) according to the manufacturer’s proto-
col. Equal amounts of protein was loaded on a 10% polyacrylamide
gel, separated by SDS–PAGE with a Mini-Protean II apparatus (Bio-
Rad Laboratories, Veenendaal, The Netherlands), and transferred
with a Trans-Blot Electrophoretic Transfer system (Bio-Rad Labora-
tories) onto a polyvinylidene difluoride membrane (PVDF; Bio-Rad
Laboratories). The membrane was blocked at room temperature for
1 h in DPBS/0.1% Tween 20 (Sigma–Aldrich; solution referred to as
PBST) containing 5% skimmed milk (Campina, Friesland, The
Netherlands) and subsequently incubated overnight at 4 C with
the appropriate primary antibody in 5% BSA (Sigma–Aldrich) or
5% skimmed milk. The following primary antibodies and dilutions
were used: NF-jB p65 (#8242, 1:2500), IjBa (#4812, 1:1000),
PARP-1 (#9532, 1:1000), HDAC 1 (#5356, 1:1000), HDAC 2
(#5113, 1:1000), HDAC 3 (#3949, 1:1000 and #2632, 1:1000); all
from Cell Signaling, Leiden, The Netherlands and anti-acetyl lysine(AB3879, 1:500; Millipore, Billerica, MA, USA). For loading control
the lower part of the blot was incubated for 1 h at room tempera-
ture with monoclonal rabbit anti-b-actin (#4970, 1:10,000; Cell
Signaling). Membranes were washed in PBST and incubated at
room temperature for 1 h with peroxidase-conjugated secondary
antibodies. The following secondary antibodies were used: goat
anti-rabbit IgG/HRP (#P0448), rabbit anti-goat IgG/HRP (#P0449)
and rabbit anti-mouse IgG/HRP (#P0260, all 1:2000; DakoCytoma-
tion, Glostrup, Denmark). The bands were visualized by the
enhanced chemiluminescence method using the Western Light-
ning Plus-ECL kit (PerkinElmer, Waltham, MA, USA), quantified
by imaging (GeneSnap from SynGene, Frederick, MD, USA), and
processed using ImageJ software (1.48d; National Institute of
Health, USA).
2.5. HDAC inhibition assay
The assay was performed in triplicate as described before [24].
Briefly, the respective human recombinant HDAC enzymes (BPS
Bioscience, San Diego, CA, USA) were incubated in absence and/
or in presence of various concentrations RGFP966 and a pro-
fluorogenic substrate at room temperature for 60 min. Next, the
deacetylation reaction was stopped by the addition of the HDAC
Stop Solution (6 mg/ml trypsin, 0.3 mM SAHA) in all wells and
the plate was incubated at 37 C for 20 min. The release of the flu-
orescent 7-amino-4-methylcoumarin was monitored by measuring
the fluorescence at kem = 460 nm and kex = 390 nm using a Synergy
H1 plate reader (BioTek Instruments, Winooski, VT, USA). The flu-
orescence value of the background wells was subtracted from the
fluorescence of the positive control, blank and inhibitor wells. Non-
linear regression was used to fit the data to the log(inhibitor) vs.
response curve using GraphPad Prism (GraphPad software 5.00,
San Diego CA, USA).
2.6. Investigation of cellular toxicity by MTS assay
To investigate the influence of the HDAC 3-selective inhibitor
RGFP966 on cell viability, RAW 264.7 macrophages, HBE cells
and hASM cells were seeded in 96-well plates. To obtain identical
cell density at the start of the experiments, RAW 264.7 macro-
phages were seeded at 25,000 cells/cm2, HBE cells and hASM cells
were seeded at 70% confluency (based on surface area) and were
serum-starved for 24 h prior incubation with RGFP966. Shortly
before incubation with RGFP966, the medium was replaced by
100 ll fresh (if appropriate serum free) culture medium. Incuba-
tions with LPS and IFNc were performed as described for HDAC
1–3 downregulation by siRNA. After 20 h of incubation with
RGFP966, 20 ll of CellTiter 96 AQueous One Solution reagent (Pro-
mega) was added to each well and incubated at 37 C for 1 h in
the dark. The absorbance at 490 nm was measured using a Synergy
H1 plate reader. LPS/IFNc-stimulated cells without addition of
RGFP966 were considered 100%.
2.7. Effect of RGFP966 on NF-jB p65 transcriptional activity by
QUANTI-Blue assay
RAW-BlueTM cells (InvivoGen, San Diego, CA, USA) were origi-
nally derived from mouse RAW 264.7 macrophages, which stably
express a secreted embryonic alkaline phosphatase (SEAP) gene
inducible by NF-jB and AP-1 transcription factors. RAW-Blue cells
were treated with RGFP966 for a total of 20 h from which the last
4 h was supplemented with 10 ng/ml LPS and 10 ng/ml INFc. The
secretion of SEAP into the medium was determined using
the QUANTI-BlueTM detection medium (InvivoGen) according to
the manufacturer’s protocol. Briefly, 50 ll of supernatant was
added to 150 ll of QUANTI-BlueTM detection medium and incubated
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assessed by measuring the absorbance at 630 nm using a Synergy
H1 plate reader. Results were plotted as % of control.
2.8. Animals
C57bl/6 male mice (weight 24–28 g; age 8–10 weeks) were
purchased from Harlan (Zeist, The Netherlands). Animals were
maintained on mouse chow and tap water ad libitum in a
humidity- and temperature-controlled room at 24 C with a 12 h
light/dark cycle. All experiments were performed according to
the national guidelines and upon approval of the experimental pro-
cedures by the local Animal Care and Use committee of Groningen
University, DEC number 6962A. Mice were randomly assigned to
the experiments.
2.9. Precision-cut lung slices and treatment
Mouse precision-cut lung slices (PCLS) were prepared as previ-
ously described (Eleftheriadis et al. [25]). Briefly, male mice were
anesthetized by subcutaneous injection of ketamine (75 mg/kg,
Alfasan, Woerden, The Netherlands) and dexdomitor (0.5 mg/kg,
Orion Pharma, Mechelen, Belgium). Subsequently, the trachea
was cannulated and the animal was exsanguinated by cutting the
jugular vein, after which the lungs were filled trough the cannula
with 1.5 ml low melting-point agarose solution (1.5% final concen-
tration). The lungs were placed on ice for 15 min to solidify the
agarose for slicing. The lobes were separated and tissue cores were
prepared of the individual lobes, after which the lobes were sliced
at a thickness of 250 lm. Tissue slices were incubated at 37 C in a
humid atmosphere under 5% CO2/95% air. In order to remove the
agarose and cell debris from the tissue, slices were washed every
30 min (four times in total).
PCLS were incubated in DMEM supplemented with sodium
pyruvate (1 mM), MEM non-essential amino acid mixture (1:100;
Gibco by Life Technologies), gentamycin (45 lg/ml; Gibco by
Life Technologies), penicillin (100 U/ml), streptomycin (100 lg/ml)
and amphotericin B (1.5 lg/ml; Gibco by Life Technologies). Slices
were cultured at 37 C in a humidified atmosphere under 5%
CO2/95% air in 12-well tissue culture plates, using 3 slices per well.
Slices were treated with RGFP966 for 20 h at final concentrations of
1 and 10 lM, and where indicated, stimulated with 10 ng/ml LPS
and 10 ng/ml IFNc.
2.10. Assessment of tissue viability using lactate dehydrogenase
To assess the viability of the PCLS subjected to RGFP966, the
amount of lactate dehydrogenase (LDH) released from the tissue
slices into the incubation medium was analyzed. Maximal LDH
release was determined by lysing 3 slices with 1% Triton X-100
for 30 min at 37 C at the start of the experiments. Supernatants
were stored at 80 C. LDH release was determined using an assay
form Roche Diagnostics (Mannheim, Germany), and was measured
using a Hitachi automatic analyzer (Modular Analytics, Roche
Diagnostics). LDH release from the PCLS into the incubation med-
ium was plotted relative to maximal LDH release.
2.11. Confocal laser scanning microscopy
The effect of the RGFP966 on the nuclear translocation of NF-jB
p65 and localization of HDAC 3 was evaluated by immunofluores-
cence. 20,000 cells/cm2 cells were seeded in Lab-Tek chambers
(#177445; Nunc, Rochester, NY, USA) and subjected to 1 lM
RGFP966 for 20 h. Cells were washed twice with ice-cold DPBS
and fixed with 4% formaldehyde at room temperature for 20 min.
Subsequently, cells were permeabilized with 0.25% Triton X-100in DPBS and blocked with DPBS/5% BSA for 30–60 min at room
temperature (to minimize non-specific binding). NF-jB p65 was
detected with rabbit monoclonal NF-jB p65 antibody (2 h incuba-
tion at 4 C, 1:250; # 8242, Cell Signaling), followed by 1 h incuba-
tion with goat anti-rabbit AlexaFluor488 (10 lg/ml; A-11008,
Molecular Probes, Leiden, The Netherlands). HDAC 3 was detected
with mouse monoclonal HDAC 3 antibody (2 h incubation at 4 C,
1:100; # 3949, Cell Signaling), followed by 1 h incubation with
goat anti-mouse AlexaFluor546 (10 lg/ml; A-11018, Molecular
Probes). All antibody incubation steps were carried out in 5%
BSA/DPBS and between incubation steps slides were washed with
DPBS/0.5% BSA/0.05% Tween 20. For negative control, samples
were processed omitting the primary antibody. At the end of
the incubation steps, nuclei were stained with Hoechst 33342
(Molecular Probes) and mounted using Aqua Poly/Mount medium
(Polysciences, Warrington, PA, USA), air dried for 24 h, and stored
in the dark at 4 C. Fluorescence was examined using a confocal
laser scanning microscope (CLSM) equipped with true confocal
scanner (TCS; SP8 Leica, Heidelberg, Germany), using a 63 oil
immersion lens. Sequential scans were obtained to avoid bleed
through. AlexaFluor488 was excited using the 488 nm blue laser
line, AlexaFluor546 was excited using the 552 nm green laser line
and Hoechst 33342 using the 405 nm UV laser line. All images
were recorded in the linear range, avoiding local saturation, at an
image resolution of 2048  2048 pixels and with a pinhole size
of 1 Airy unit. Presented images show a single z-scan. Images were
further processed using ImageJ 1.48d.
2.12. Nuclear and cytosolic fractionation
RAW 264.7 macrophages were subjected to 1 lM RGFP966 for
20 h, stimulated with 10 ng/ml LPS and 10 ng/ml IFNc for 4 h
and subsequently lysed. Nuclear and cytosol fractions of RAW
264.7 macrophages were prepared using the NE-PER Nuclear
and Cytoplasmic Extraction kit (Thermo Scientific) according to
the protocol of the manufacturer.
2.13. Cell lysis and immunoprecipitation of NF-jB p65
RAW 264.7 macrophages (175 cm2) were subjected to 1 lM
RGFP966 for 20 h, stimulated with 10 ng/ml LPS and 10 ng/ml IFNc
for 1 h and subsequently lysed in lysis buffer (20 mM Tris–HCl pH
7.5, 120 mMNaCl, 1% IGEPAL CA-630, 2 mM EDTA; all from Sigma–
Aldrich) supplemented with protease inhibitors (#88266; Thermo
Scientific). Lysates were incubated at 4 C with constant rotation
for 4 h and cleared by centrifugation (14,000g, 10 min, 4 C).
Cleared lysates were incubated with mouse monoclonal NF-jB
p65 antibody (#6956, 1:100 (v/v); Cell Signaling) overnight at
4 C. Subsequently, lysates were incubated with 50 ll of Protein
A/G PLUS-Agarose Immunoprecipitation Reagent (sc-2003; Santa
Cruz Biotechnology, Inc., Dallas, TX, USA) at constant rotation for
6 h at 4 C. Protein A/G agarose bound immunocomplexes were
precipitated by centrifugation (4000g, 5 min, 4 C) and washed 3
times with ice-cold lysis buffer. The pellet was re-suspended in
100 ll of 1 SDS sample buffer, boiled (95 C, 5 min), and cleared
by centrifugation (14,000g, 1 min).
2.14. Histone extraction and Micro BCATM protein assay
Histone extractions were performed as previously described in
the literature with minor modifications [26]. After histone extrac-
tions the samples were diluted with Phosphate-Buffered Saline
(PBS; PAA Laboratories GmbH, Austria) to determine the total pro-
tein concentration using the micro BCA protein assay according to
the manufacturer’s instructions (Pierce, Rockford, USA, # 23235).
Absorbance was measured with a Synergy H1 plate reader at
62 N.G.J. Leus et al. / Biochemical Pharmacology 108 (2016) 58–74562 nm. A bovine serum albumin standard (2 mg/ml, Pierce, Rock-
ford, USA, # 23209) was used to calibrate the assay.
2.15. Acetylation of histones with acetic anhydride-d6
For the reaction, 7 lg of histones were loaded on a 15% poly-
acrylamide gel and resolved by SDS-PAGE electrophoresis. After
Coomassie staining, bands for histones H3 and H4 were excised
from the gel. Then 50 ll of acetonitrile and 50 ll of ammonium
bicarbonate buffer (100 mM) were added to destain the gel bands.
Gel bands were then dried in acetonitrile. Subsequently, 5 ll of
acetic anhydride-d6 was added, after which 100 ll of ammonium
bicarbonate (1 M) was added immediately. Subsequently, samples
were incubated at 37 C for 15 min. Gel bands were then washed 3
times with H2O. The acetic anhydride-d6 reaction was then
repeated. After the second reaction, gel bands were dried using
acetonitrile and trypsin (Promega, Madison, Wisconsin, USA,
#V511A) was added at a 1:20 ratio in ammonium bicarbonate
(50 mM). Histones were digested at 37 C for 16 h. Supernatants
containing histone peptides were subjected to LC MS/MS analysis
as described below.
2.16. NanoChip LC–MS/MS QTOF
A quadruple time-of-flight mass spectrometer (QTOF, Agilent
6510) with a liquid chromatography-chip cube (#G4240) electro-
spray ionization interface was coupled to a nanoLC system (Agilent
1200) composed of a nanopump (#G2226A), a capillary loading
pump (#G1376A) and a solvent degasser (#G1379B). Injections
were performed with an autosampler (#G1389A) equipped with
an injection loop of 40 ll and a thermostated cooler maintaining
the samples in the autosampler at 4 C during the analysis
(#G1377A Micro WPS). The instrument was operated under the
MassHunter Data Acquisition software (Agilent Technologies,
Santa Clara, USA, version B.04.00, B4033.3). A chip (ProtID-
Chip-150 II 300A, #G4240-62006) with a 40 nl trap column and a
75 lm  150 mm analytical column filled with Zorbax 300SB-
C18, 5 lm (Agilent Technologies) was used for peptide separation.
The following mobile phases were used for LC separations: sol-
vent A, ultrapure water (resistance 18.2 MO, Millipore) with 0.1%
(v/v) formic acid (FA), and solvent B, acetonitrile (ACN) with 0.1%
(v/v) FA. The samples were injected and trapped at a flow rate
4.0 ll/min in a solution of 3% (v/v) ACN and 0.1% (v/v) FA in
ultrapure water. The flow rate for peptide separation was
0.25 ll/min. The following program was used for elution peptides:
0–3 min linear gradient from 3% to 10% solvent B; 3–65 min linear
gradient to 35% solvent B; 65–75 min linear gradient to 50%
solvent B; 75–80 min linear gradient to 90% solvent B;
80–82 min isocratic 90% solvent B; 82–82.5 min linear gradient
to 3% eluent B; 82.5–90 min isocratic 3% solvent B.
The identification of peptides was based on data collected in
auto MS/MS 2 GHz mode using the following settings; fragmentor:
175 V, skimmer: 65 V, OCT 1 RF Vpp: 750 V, precursor ion selec-
tion: medium (4m/z), mass range: 200–2500m/z, acquisition rate
for MS: 2 spectra/s, for MS/MS 3 spectra/s; MS/MS range: 50–
3000m/z; ramped collision energy: slope 3.8, offset: 0, precursor
setting: maximum 3 precursors/cycle; absolute threshold for peak
selection was 1000; relative threshold was 0.01% of the most
intense peak, active exclusion enabled after 1 selection, release of
active exclusion after 0.6 min, precursors were sorted by abun-
dance only. The MS/MS files were stored in centroid and profile
mode. MS1 absolute threshold 50 and MS2 absolute threshold 35
were applied to account for detector noise. Static exclusion range
200–350m/z for precursor selection was applied. Gas temperature
(nitrogen) was 325 C and gas flow was 5 l/min. The quantification
of peptides was based on data collected in MS mode using thesame settings except of the mass range 20–3000m/z; acquisition
rate 1 spectra/s. In both cases lock masses 1221.990m/z and
299.294 (Agilent) were used to recalibrate spectra during the
acquisition. The area of the manually extracted ion chromatograms
(0.1m/z tolerance) of the selected peptides was used for label-free
quantification.2.17. Database search
Tandem mass spectra were extracted, charge state deconvo-
luted and deisotoped by the MassHunter Qualitative Analysis soft-
ware version B.05.00 (Agilent Technologies) and saved as .mgf files.
All MS/MS data were analyzed using Phenyx (GeneBio, Geneva,
Switzerland); version CYCLONE (2010.12.01.1)). The fragment ion
mass tolerance of 0.30 Da and a parent ion tolerance of 400 ppm
were selected for a database search. The oxidation of methionine
(+15.99), light (+42.01) and heavy (+45.03) acetylation of lysine
(K), heavy acetylation with light methylation (+59.045) of K,
methylation (+14.01), dimethylation (+28.03), trimethylation
(+42.04) of K, methylation of arginine (R) (+14.01), dimethylation
of arginine (R) (+28.03) N-terminal acetylation (+42.01), deamida-
tion (+0.98) of asparagine (N) and glutamine (Q) were specified in
Phenyx as variable modifications. The database search was per-
formed in 2 steps. First, Phenyx was setup to search the uniprot
swissprot database (selected for Mus musculus, Release 2012_08
of 05-Sep-12, 16547 sequences) setting the digestion enzyme to
trypsin with up to one allowed missed cleavage site to identify a
set of histones in the sample. Second, database search against the
selected protein sequences (P43276, P43277, P43274, P43275,
P15864, P10853, Q64525, Q8CGP1, P0C0S6, P68433, P62806,
Q8CGP6, Q8R1M2, Q64523, P27661, P10922, Q9D1P2, O55128)
was performed setting the digestion enzyme to trypsin with up
to five allowed missed cleavage sites.2.18. Statistical analysis
Statistical analysis of the results was performed by a two-tailed
unpaired Student’s t-test, assuming equal variances to compare
two replicate groups. Analysis of differences between multiple
replicate groups was analyzed with a one-way ANOVA followed
by Bonferroni post hoc analysis. p values 60.05 were considered
to be significant. Data were analyzed with GraphPad Prism.3. Results
3.1. Downregulation of HDAC 3 attenuates the LPS/IFNc-induced
expression of pro-inflammatory genes and upregulates anti-
inflammatory gene expression in RAW 264.7 macrophages
Among the class I HDACs, activity of HDAC 3 has been described
to play a key role in pro-inflammatory gene expression [27]. In
order to establish the role of class I HDACs 1, 2 and 3 in our model
we explored the gene expression of TNFa, iNOS, IL-1b, IL-6, IL-10
and IL-12b in mouse LPS/IFNc-stimulated RAW 264.7 macrophages
upon HDAC 1, 2 and 3 downregulation. HDAC 1, 2 and 3 gene
expression was downregulated by 50–80%, as compared to control
using specific siRNAs (Fig. 1A), which was corroborated by down-
regulation of HDAC 1–3 protein expression (Fig. 1B). We investi-
gated the expression of pro- and anti-inflammatory genes in
RAW 264.7 macrophages in response to inflammatory stimulation
using LPS and INFc to ensure classical activation toward M1 (pro-
inflammatory) macrophages. LPS/IFNc stimulation did not affect
the gene expression levels of HDACs 1–3 in RAW 264.7 macro-
phages (data not shown).
Fig. 1. Downregulation of HDAC 3 by siRNA reduced the mRNA expression of LPS/IFNc-induced pro-inflammatory genes and upregulated the anti-inflammatory gene IL-10 in
LPS/IFNc-stimulated RAW 264.7 macrophages. 20 h after transfection with HDACs 1, 2 and 3 or negative control siRNA RAW 264.7 macrophages were stimulated with LPS/
IFNc for the last 4 h of the experiment. HDACs 1, 2 and 3 gene expression was expressed as fold change compared to control (LPS/IFNc-treated) group (A). Data are presented
as mean values ± SD of 4–9 independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001 compared to the control (LPS/IFNc-treated) group. Immunoblot that corroborate
downregulation of HDACs 1, 2 and 3 is shown in (B). The presented data set shows a representative blot of 3 independent experiments performed under inflammatory (LPS/
IFNc) conditions. Inflammatory gene expression was assessed by RT-qPCR and expressed as fold change compared to control (LPS/IFNc-treated) group (C). Data are presented
as mean values ± SD of 4–9 independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001 compared to the control (LPS/IFNc-treated) group.
N.G.J. Leus et al. / Biochemical Pharmacology 108 (2016) 58–74 63
64 N.G.J. Leus et al. / Biochemical Pharmacology 108 (2016) 58–74Downregulation of HDAC 1 in LPS/IFNc-stimulated RAW 264.7
macrophages significantly reduced the expression of the pro-
inflammatory gene IL-1b, whereas the expression of other genes
remained largely unaltered (Fig. 1C). The expression of the pro-
inflammatory genes was largely unaffected upon HDAC 2 down-
regulation, while HDAC 3 downregulation reduced the expression
of the pro-inflammatory genes IL-1b, IL-6 and IL-12b up to 60%,
and upregulated the expression of the anti-inflammatory gene IL-
10 by 2-fold compared to control. The observed pro-
inflammatory role for HDAC 3 is in line with recent literature
[14,27] as described in the introduction. Taken together, this justi-
fies the investigation of a pharmacological HDAC 3-selective inhi-
bitor in model systems to examine alleviation of inflammatory
lung diseases.
3.2. The pharmacological HDAC 3-selective inhibitor RGFP966
attenuates the inflammatory gene expression in LPS/IFNc-stimulated
RAW 264.7 macrophages and mouse precision-cut lung slices
Having established HDAC 3 as an important HDAC iso-enzyme
in (co)regulating inflammatory gene expression we moved on to
study which molecular consequences are associated with HDAC 3
inhibition in model systems for pulmonary inflammation, using
the pharmacological HDAC 3-selective inhibitor RGFP966. As a first
step we verified the IC50 values of RGFP966 against the deacetylase
activity of recombinant human HDACs 1–3 and 8 [18,19]. RGFP966
potently and selectively inhibited HDAC 3 at nanomolar concentra-
tions, while HDACs 1, 2 and 8 were not inhibited at such concentra-
tions, (Fig. 2A) indicating a good level of selectivity for HDAC 3. As
a reference, we included the well-studied pan-HDAC inhibitor
SAHA for which we confirmed its lack of selectivity among class I
HDAC iso-enzymes (Fig. 2B).
Next, RGFP966 was applied in cell-based model systems for
inflammatory lung diseases using mouse RAW 264.7 macrophages,
human bronchial epithelial (HBE) cells and human airway smooth
muscle (hASM) cells that were subjected to LPS/IFNc-stimulation.
First, we investigated the cytotoxicity of RGFP966 in these cell
types and observed no significant decrease in cell viability at the
applied concentrations, as compared to control cells (data not
shown). In LPS/IFNc-stimulated RAW 264.7 macrophages treat-
ment with RGFP966 did not change the expression of the genes
TNFa, iNOS, and IL-10 but provided a significant downregulation
of the expression of the pro-inflammatory genes IL-1b, IL-6 and
IL-12b (Fig. 2C). This effect was specific for macrophages as in
HBE cells and hASM cells the expression of the investigated genes
was not affected except for pro-inflammatory gene IL-6, which was
upregulated in HBE cells. For comparison, the pan-HDAC inhibitor
SAHA upregulated IL-1b expression in RAW 264.7 macrophages
demonstrating the differential effects observed for pan-HDAC inhi-
bition compared to HDAC 3-selective inhibition (Fig. 2C). The
observed differential effects on different cell types clearly demon-
strates that the effects of HDAC inhibitors are cell type dependent
and that HDAC 3 inhibition is particularly effective in repressing
pro-inflammatory responses in macrophages.
To study the influence of RGFP966 treatment on the expression
of LPS/IFNc-induced cytokines in a more complex model system
for inflammatory lung diseases we applied mouse precision-cut
lung slices (PCLS) (Fig. 3A), which represent all cell types present
in the in vivo situation and conserve the original architecture and
matrix environment. Although PCLS do not have abundant inflam-
matory cells, tissue resident macrophages, epithelial cells and
smooth muscle cells are present. First, the effect of RGFP966 treat-
ment on the viability of PCLS was determined by measuring the
release of lactate dehydrogenase (LDH) into the culture medium,which demonstrated no significant increase in LDH release upon
RGFP966 treatment up to concentrations of 610 lM (data not
shown). Next, we examined the expression of pro-inflammatory
genes TNFa, iNOS, IL-1b, IL-6, IL-12b, and the anti-inflammatory
gene IL-10 in PCLS (either untreated or stimulated with LPS/IFNc
for 4 h), which confirmed robust induction of their expression
(data not shown). Upon RGFP966 treatment, the expression of
the anti-inflammatory gene IL-10 was upregulated by 2-fold in
PCLS (Fig. 3B). This was accompanied by upregulation of the Fizz1
gene (Fig. 3C), which is a marker gene for the anti-inflammatory
M2 phenotype of macrophages [28]. In addition, the expression
of pro-inflammatory genes iNOS and IL-12b was significantly
downregulated, and in contrast to our previous observations in
RAW 264.7 macrophages, expression of the pro-inflammatory gene
IL-1b was increased by more than 2-fold in PCLS (Fig. 3B). The
expression of the investigated inflammatory genes in PCLS
remained unaltered upon treatment with the pan-HDAC inhibitor
SAHA (Fig. 3B). Taken together, since IL-10 has anti-inflammatory
properties and is connected with the anti-inflammatory M2macro-
phage phenotype, the observed changes in IL-10 expression are
indicative for a potential anti-inflammatory effect of RGFP966 in
inflammatory lung diseases, which is corroborated by the observed
increased Fizz1 expression, and the attenuation of iNOS and IL-12b
expression.
3.3. RGFP966 attenuates LPS/IFNc-induced NF-jB p65 transcriptional
activity but does not affect NF-jB p65 acetylation, nuclear
translocation, IjBa activation, or the overall histone acetylation status
in RAW 264.7 macrophages
Inflammatory responses are frequently driven by well-defined
stimulus-regulated transcription factors such as NF-jB p65. NF-
jB p65 activation is required for the (in)direct expression of e.g.,
TNFa, iNOS, IL-1b, IL-6, IL-8, IL-10 and IL12b [29]. A number of bio-
chemical studies have shown that HDAC 3 is involved in the
deacetylation of the NF-jB p65 subunit, leading to activation of
its transcriptional activity [14,30]. Therefore, we investigate
whether the observed attenuation of pro-inflammatory responses
by the HDAC 3-selective inhibitor RGFP966 is connected to
changes in NF-jB p65 transcriptional activity and lysine
acetylation.
First, the transcriptional activity of NF-jB p65 was assessed
using a reporter gene assay. As shown in Fig. 4A, RGFP966 provided
a robust reduction of the transcriptional activity of NF-jB p65. In
contrast, the pan-HDAC inhibitor SAHA increased the transcrip-
tional activity of NF-jB p65. Subsequently, changes in the acetyla-
tion status of NF-jB p65 upon RGFP966 treatment were
investigated using Western blot (Fig. 4B) and quantified by densit-
ometric analysis (Fig. 4C). Using this method, no changes in the
total acetylation of NF-jB p65 in RAW 264.7 macrophages were
observed upon treatment with the HDAC 3-selective inhibitor
RGFP966, indicating that HDAC 3 inhibition does not inhibit NF-
jB p65 transcriptional activity by its deacetylation but rather by
other mechanisms such as inhibition of co-activation of its tran-
scriptional activity.
Next to NF-jB p65 acetylation, histone lysine acetylation was
analyzed. Histones were extracted from RAW 264.7 macrophages
and the acetylation levels of histone H3 and H4 were assessed by
Western blot. RAW 264.7 macrophages subjected to HDAC 3 inhi-
bitor RGFP966 showed no alteration in histone acetylation com-
pared to vehicle-treated cells (Fig. 4D). In order to assess the
changes in lysine acetylation on specific residues, histone acetyla-
tion of histone H3 and H4 was analyzed using mass spectrometry.
To enable quantification, a previously described approach was
Fig. 2. HDAC 3-selective inhibitor RGFP966 attenuates the expression of pro-inflammatory genes in RAW 264.7 macrophages. IC50 values of RGFP966 (A) and the pan-HDAC
inhibitor SAHA (B) against the deacetylase activity of recombinant human class I HDACs 1, 2, 3 and 8 were determined. Inhibitory potency of RGFP966 and SAHA is shown in
red. The log IC50 values are presented as mean values (lM) of 3 independent experiments ± SD. Subsequently, RAW 264.7 macrophages, human bronchial epithelial (HBE)
cells and human airway smooth muscle (hASM) cells were incubated with RGFP966 and SAHA for 20 h and stimulated with LPS/IFNc for the last 4 h of the experiment (C).
Gene expression was assessed by RT-qPCR and expressed as fold change compared to control (LPS/IFNc-treated) group. Data are presented as mean values ± SD of 3–5
independent experiments. **p < 0.01; ***p < 0.001 compared to vehicle. N.D. = not determined or not detected. (For interpretation of the references to color in this figure legend,
the reader is referred to the web version of this article.)
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deuterated acetic acid anhydride ((CD3CO)2O) as a reagent
[31–34]. Using this method deuterated acetyl groups were
installed on non-acetylated lysine residues. Subsequent tryptic
digestion results in C-terminal cleavage at arginine residues,
generating peptide fragments that are subjected to LC–MS/MS
analysis. Based on the mass difference between deuterated and
non-deuterated lysine acetylations the endogenous lysine acetyla-
tion ratio can be determined. Using this method a comprehensive
overview of histone H3 and histone H4 acetylations was obtained
(histone H3 peptide 18–26: KQLATKAAR and histone H4 peptide
4–17: GKGGKGLGKGGAKR are depicted in Fig. 4E). These and other
peptides of histone H3 and histone H4 did not show changes in
lysine acetylation status upon RGFP966 treatment, whereas SAHA
treatment resulted in significant increases in histone lysine acety-
lation. This indicates that HDAC 3-selective inhibition does not
induce global changes in histone lysine acetylations as observed
for the pan-HDAC inhibitor SAHA (Fig. 4E).
In order to explore the influence of pharmacological HDAC 3
inhibition on NF-kB-mediated signaling further the effect of
RGFP966 on nuclear translocation was investigated using fluores-
cence microscopy. No alterations in NF-jB p65 nuclear localization
were observed upon RGFP966 treatment (Fig. 5A), which was con-
firmed by cellular fractionation experiments in which the nuclear
and cytosolic fractions were separated and blotted for NF-jB p65
(Fig. 5B and C). In addition, to confirm proper LPS/IFNc-
stimulation and to determine the levels of IjBa in the presence
of RGFP966, IjBa expression was assessed by Western blotting
(Fig. 5D). These results demonstrate that HDAC 3-selective inhibi-
tion by RGFP966 does not affect IjBa activation. Taken together,
these results indicate that HDAC 3-selective inhibitor RGFP966
pharmacologically attenuates NF-jB p65 transcriptional activity,
but does not affect NF-jB p65 acetylation, histone H3 and H4
acetylation, IjBa activation or NF-jB p65 nuclear translocation
in RAW 264.7 macrophages.3.4. HDAC 1–3 localization, expression and HDAC 3 – NF-jB p65
interaction in RGFP966-mediated attenuation of the LPS/IFNc-induced
inflammatory response in RAW 264.7 macrophages
Recently, it was demonstrated that HDAC inhibitors are able to
affect HDAC expression levels and localization, besides attenuating
HDAC activity [35,36]. This prompted us to determine the expres-
sion levels of HDACs 1, 2 and 3 and to investigate their localization
in LPS-induced RAW 264.7 macrophages.
The mRNA levels of HDACs 1, 2 and 3 were not significantly
affected by RGFP966 in RAW 264.7 macrophages (Fig. 6A), whereas
the HDAC 1 and HDAC 2 protein levels were slightly, though signif-
icantly, reduced upon RGFP966 treatment (Fig. 6B and C). In addi-
tion, neither mRNA nor protein levels of NF-jB p65 and IjBa were
affected by RGFP966 in RAW 264.7 macrophages (Fig. 6A). In con-
trast, in PCLS, both mRNA and protein levels of HDACs 1, 2 and 3
were not affected by RGFP966, however, the IjBa level was signif-
icantly upregulated (data not shown). Moreover, differences in
HDAC expression as reflected by, for example, the different basal
mRNA expression of HDACs 1, 2 and 3 in cells and PCLS, might
guide alterations of (pro)inflammatory gene expression.
In order to evaluate if RGFP966 treatment influences NF-kB p65
activation by alteration of the localization of HDACs the influence
of this inhibitor on the localization of NF-jB p65 and HDACs 1, 2
and 3 was investigated. The localization of HDACs 1–3 was studied
by fluorescence microscopy (Fig. 7A) and Western blotting of
nuclear and cytosolic fractions (Fig. 7B). As shown in
Fig. 7A and B, no differences in HDAC 1, 2 and 3 localization were
observed in RGFP966-treated RAW 264.7 macrophages compared
to vehicle control.
Considering that pharmacological HDAC 3-selective inhibition
reduced the NF-jB p65 transcriptional activity while leaving the
NF-jB p65 acetylation and nuclear localization of NF-jB p65 and
HDAC 3 unaltered suggests that HDAC 3 inhibition affects the
NF-jB p65 transcriptional activity as a co-activator and not as a
Fig. 3. Effect of pharmacological HDAC 3 inhibition on the (pro)inflammatory gene expression profile in mouse precision-cut lung slices. Schematic representation of the
experimental setup and timeline (A). Mouse precision-cut lung slices (PCLS) were subjected to RGFP966 and SAHA for 20 h and stimulated with LPS/IFNc for the last 4 h of the
experiment and subsequently lysed. Inflammatory gene expression was assessed by real-time PCR and expressed as fold change compared to control (LPS/IFNc-treated)
group (B). Effect of HDAC 3 inhibition on M2marker gene expression in PCLS is shown in (C). Data are presented as mean values ± SD; n = 3–5. *p < 0.05; **p < 0.01 compared to
vehicle. N.D. = not determined for SAHA.
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stimulated RAW 264.7 macrophages. Therefore, the interaction of
HDAC 3 with NF-jB p65 was investigated by immunoprecipitationof NF-jB p65 and Western blot for HDAC 3 (Fig. 7C). As shown in
Fig. 7C the interaction of HDAC 3 with NF-jB p65 was not affected
in RGFP966-treated RAW 264.7 macrophages compared to
Fig. 4. HDAC 3-selective inhibitor RGFP966 attenuates LPS/IFNc-induced NF-jB p65 activity but affects neither the NF-jB p65 acetylation nor the histone acetylation status in
RAW 264.7 macrophages. RAW-Blue cells were subjected to RGFP966 and SAHA for 20 h and stimulated with LPS/IFNc for the last 4 h of the experiment. In the absence of an
inflammatory stimulus, treatment of RAW-Blue cells with HDAC inhibitors did not affect the secretion of embryonic alkaline phosphatase (SEAP; data not shown), whereas
treatment of RAW-Blue cells with RGFP966 followed by a pro-inflammatory stimulus significantly reduced the secretion of SEAP (A). Data are presented asmean values ± SD of
3–4 independent experiments. ***p < 0.001, compared to vehicle-treated group. The effect of HDAC 3 inhibition on total NF-jB p65 acetylation was assessed by
(B) immunoblotting and quantified by densitometric analysis (C). RAW 264.7 macrophages were incubated with HDAC inhibitors for 20 h and subsequently lysed. For the
detection of NF-jB p65 acetylation, lysates were incubated and immunoprecipitated with 5 lg of mouse monoclonal NF-jB p65-specific antibody as described. Data are
presented asmean values ± SD expressed as fold change compared to control (vehicle-treated) group of 4 independent experiments. Histoneswere separated on SDS–PAGE (D),
subsequently histones H3 and H4were excised from the gel. Gel pieces were treatedwith acetic anhydride d6, followed by trypsin digestion. Resulting peptides were subjected
to LC–MS/MS analysis (E). RGFP966 treatment did not affect the acetylation status of histone H3 (res. peptide 18–26: KQLATKAAR) and histone H4 (res. peptide 4–17:
GKGGKGLGKGGAKR), whereas SAHA increased acetylation status of both peptides. Data are presented as mean values ± SD of 3–5 independent experiments. No significant
differences were observed between untreated and vehicle treated cells (data not shown).
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Fig. 5. RGFP966 does not affect the nuclear translocation of NF-kB p65 in RAW 264.7 macrophages. After 20 h incubation with RGFP966 followed by 1 h LPS/IFNc stimulation,
RAW 264.7 macrophages were prepared for immunofluorescence microscopy (A). Green signal represents NF-kB p65 protein, while the blue signal visualizes the
Hoechst-stained nuclei. RGFP966 did not affect the nuclear translocation of NF-kB p65 compared to (vehicle-treated) control group. The presented data set shows
representative images of 3 independent experiments, original magnification 400. All images were taken under identical instrumental conditions. In addition, the effect of
RGFP966 on NF-kB p65 translocation in LPS/IFNc-stimulated RAW 264.7 macrophages was analyzed by immunoblotting cell fractions (B) and quantified by densitometric
analysis (C). PARP-1 and b-actin were used as internal controls. Data are presented as mean values ± SD expressed as fold change compared to control (LPS/IFNc-treated)
group of 4 independent experiments. RAW 264.7 macrophages were stimulated with 10 ng/ml LPS/IFNc for 15, 30 and 60 min and subsequently lysed. In parallel, to confirm
proper LPS/IFNc-stimulation and to determine the levels of IjBa in the presence of RGFP966, IjBa expression was assessed by Western blotting (D). b-Actin was used as
loading control. The presented data set shows a representative blot of 3 independent experiments. (For interpretation of the references to color in this figure legend, the
reader is referred to the web version of this article.)
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Fig. 6. HDAC 3-selective inhibitor RGFP966 reduces the protein expression of HDAC 1 and HDAC 2 in RAW 264.7 macrophages. RAW 264.7 macrophages were incubated with
RGFP966, stimulated for 4 h with LPS/IFNc and subsequently harvested. Gene expression of NF-kB p65, IjBa, HDAC 1, HDAC 2 and HDAC 3 was analyzed by real-time qPCR
(A). Data are presented as mean values ± SD; n = 3–4. In parallel, the effect of RGFP966 on total NF-kB p65 and HDAC 1–3 protein expression in LPS/IFNc-stimulated RAW
264.7 macrophages was analyzed by immunoblotting (B) and quantified by densitometric analysis (C). Protein levels were normalized against b-actin and control (LPS/IFNc-
treated) cells were set at 100%. Data are presented as mean values ± SD of 4 independent experiments and a representative blot is shown in B. *p < 0.05; **p < 0.01 compared to
vehicle.
70 N.G.J. Leus et al. / Biochemical Pharmacology 108 (2016) 58–74vehicle-treated RAW 264.7 macrophages. Taken together, these
results demonstrate that NF-jB p65 transcriptional activity is
influenced by HDAC 3 enzymatic activity, while its acetylation,
nuclear translocation as well as the localization and expression
of HDACs 1, 2 and 3 remains unaltered in LPS/IFNc-stimulated
mouse RAW 264.7 macrophages.4. Discussion
Class I HDACs 1, 2 and 3 play key roles in the regulation of pro-
inflammatory gene expression in immune cells with a particular
pro-inflammatory role for HDAC 3 [4,14]. HDAC 3 has beenreported to be an important player in inflammation by deacetylat-
ing NF-jB p65, which has been implicated in the pathology of
COPD. Therefore, we investigated the application of a pharmaco-
logical HDAC 3-selective inhibitor in model systems for inflamma-
tory lung diseases, to explore potential therapeutic applications.
As a first step we investigated the influence of HDACs 1, 2 and 3
on attenuating (pro)inflammatory gene expression in mouse RAW
264.7 macrophages by siRNA-mediated downregulation of HDACs
1, 2 and 3. Downregulation of HDAC 1 significantly reduced the
expression of IL-1b, whereas the expression of other genes
remained unaffected (Fig. 1C). Contrary to our findings, Serrat
et al. demonstrated that downregulation of HDAC 1 (using siRNA)
in bone marrow-derived macrophages led to a reduction of
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reduction of LPS-induced IL-1b or TNFa [37]. Opposite to these
anti-inflammatory effects, HDAC 1 has been described as a
co-repressor of NF-jB p65-mediated gene expression [38]. In addi-
tion, it has been reported that HDAC 1 downregulation leads to a
prolonged NF-jB p65 phosphorylation and nuclear localization
[39]. Taken together, these studies demonstrate a versatile role
for HDAC 1 in inflammation.
HDAC 2 downregulation in RAW 264.7 macrophages resulted in
an increased expression of TNFa, iNOS and IL-6 indicating an anti-
inflammatory role for HDAC 2, which is in line with literature
(Fig. 1C). Recently it was demonstrated that HDAC 2 represses
expression of IL-6 in dendritic cells [40]. Moreover, this enzyme
has been shown to play a role in chronic obstructive pulmonary
disease (COPD). HDAC 2 levels were significantly reduced in the
lungs of patients with COPD with expression levels being reported
at less than 5% of that in control lungs [41]. Similarly, it was
reported that HDAC 2 levels were reduced in smoking asthmatics
compared to non-smoking asthmatics [42]. Furthermore, transfec-
tion of HDAC 2 in alveolar macrophages has been shown to restore
corticosteroid resistance [43]. Taken together, these studies
demonstrate versatile roles for HDAC 2 in different types of
immune cells or in different disease models, and call for a more
profound investigation of the role of HDAC 2 in inflammation.
HDAC 3 downregulation reduced the expression of IL-1b, IL-6
and IL-12b in RAW 264.7 macrophages and increased the expres-
sion of IL-10 (Fig. 1C). These findings are in line with studies that
demonstrated that HDAC 3-deficient macrophages were unable
to express almost 50% of inflammatory genes studied when
stimulated with LPS [27]. Importantly, a study by Ziesché et al.
provided similar evidence and indicated that HDAC 3 is involved
in deacetylation of the NF-jB p65 transcription factor and acts as
a co-activator of this transcription factor in IL-1-signaling [14]. In
support of these findings, studies in mice identified HDAC 3 as a
mediator of allergic skin inflammation [44]. Taken together, our
data on the role of HDAC 3 in macrophages are consistent with
literature thus strengthening the evidence that HDAC 3 inhibition
has potential to shift inflammatory gene expression toward an
anti-inflammatory profile.
In order to get insights into the effects of pharmacological HDAC
3 inhibition mediated by RGFP966 on cell-based model systems
that are relevant to inflammatory lung diseases we compared the
expression of selected pro- and anti-inflammatory genes in
response to LPS/IFNc stimulation in RAW 264.7 macrophages,
HBE cells and hASM cells. When studied in RAW 264.7 macro-
phages, expression of the IL-1b, IL-6 and IL-12b genes was signifi-
cantly downregulated in response to RGFP966 treatment, which is
in line with the observed downregulation of HDAC 3 expression by
siRNA. In contrast, IL-6 was upregulated in HBE cells and not
affected in hASM cells (Fig. 2C). This clearly demonstrates that
the anti-inflammatory effect of HDAC 3-selective inhibition is cell
type dependent and targets macrophages primarily.
In order to determine the overall effects of pharmacological
HDAC 3 inhibition on pro- and anti-inflammatory gene expression
in lung tissue, mouse PCLS were employed. In PCLS the IL-12b
expression was inhibited but in contrast to RAW 264.7 macro-
phages the IL-1b and IL-6 expression were either unaffected or
slightly upregulated. Moreover, the anti-inflammatory gene IL-10
was upregulated in PCLS (Fig. 3B), which was accompanied by
upregulation of the M2 maker gene Fizz1 (Fig. 3C) and downregu-
lation of the pro-inflammatory genes iNOS (Fig. 3B). Why effects of
RGFP966 on the expression of pro-inflammatory genes iNOS, IL-1b
and FIZZ1 are different at 1 lM versus 10 lM is not understood.
Overall, analysis of the expression of the investigated genes in
LPS/IFNc-stimulated PCLS indicates a shift from pro- to anti-
inflammatory gene expression.Discrepancies between the cell-based model systems and PCLS
can be attributed to differences in cellular composition, cellular
communication and cellular microenvironment. Therefore, the
studies in PCLS represent an important step toward application
of the HDAC 3-selective inhibitor RGFP966 in animal models for
airway inflammation. Our data demonstrate the relevance of
testing potential novel therapeutics in multiple cell types, and/or
tissue of a relevant disease model, to better predict and understand
the outcome of drug interventions in an animal model.
The effect of RGFP966 on IL-10 expression levels is remarkable.
The important role of IL-10 in inflammatory lung diseases has been
previously highlighted in a study that showed diminished IL-10
production in lung tissue of COPD patients after LPS stimulation
as compared to lung tissue of patients with normal lung function
[45]. In addition, it has been demonstrated that the level of IL-10
and the number of IL-10-positive macrophages in sputum of COPD
patients and healthy smokers was decreased as compared to
healthy non-smokers [46]. This suggests that macrophages in
COPD have lost their ability to produce anti-inflammatory cytoki-
nes such as IL-10 and are therefore unable to effectively dampen
inflammation, which could be relieved by pharmacological HDAC
3 inhibition. In line with the increased expression of the anti-
inflammatory gene IL-10 also the M2 marker gene Fizz1 increases
upon RGFP966 treatment. Taken together, both the increased
expression of IL-10 and Fizz1 indicate an anti-inflammatory effect
for RGFP966 treatment on macrophages in ex vivo studies on PCLS.
A study on the molecular mechanism of action of HDAC 3 inhi-
bitor RGFP966 was performed in LPS/IFNc-stimulated RAW 264.7
macrophages in order to compare pharmacological inhibition to
the current literature on biochemical downregulation of HDAC 3
expression. In our studies we observed that RGFP966 treatment
inhibited NF-jB transcriptional activity, which is in line with the
literature describing HDAC 3 as an NF-jB p65 co-activator
[14,27,44]. The co-activator role of HDAC 3 has been reported to
involve deacetylation of NF-jB p65 in experiments with overex-
pression of HDAC 3, which has not been observed in our studies
using RGFP966.
It has been described that the duration of the nuclear action of
NF-jB p65 is regulated by reversible acetylation and HDAC 3 has
been shown to play a role in this process [10,14]. HDAC
3-mediated deacetylation of NF-jB p65 promotes IjBa binding
and nuclear export. Therefore, we investigated the cellular local-
ization of NF-jB p65 upon RGFP966 treatment in RAW 264.7
macrophages. In our experiments we did not observe changes in
nuclear localization, which is in line with our observation that
RGFP966 did not affect NF-jB p65 acetylation. The observations
in our model that pharmacological HDAC 3 inhibition does not lead
to NF-jB p65 deacetylation and does not lead to altered NF-jB p65
localization despite the change in NF-jB p65 transcriptional
activity point to a mechanism in which HDAC 3 activity plays a
co-activator role in NF-jB p65-mediated signaling that is indepen-
dent from NF-jB p65 deacetylation and localization.
It has been described that HDAC inhibitors also affect the
acetylation levels of histone H3 and H4. Analysis of the global
acetylation levels of histone H3 and histone H4 using mass spec-
trometry revealed no changes upon RGFP966 treatment. This indi-
cates that pharmacological HDAC 3 inhibition has no wide-spread
effects on histone acetylation. At the mRNA level, RGFP966 did not
affect the expression of HDACs 1, 2 and 3 in RAW 264.7 macro-
phages (Fig. 6A). At the same time, however, the protein levels of
HDACs 1 and 2 were slightly but significantly reduced (Fig. 6C).
In addition, the localization of HDACs 1, 2 and 3 was not affected
in RGFP966-treated RAW 264.7 macrophages compared to
vehicle-treated cells. This argues for a model in which pharmaco-
logical HDAC 3 inhibition has a pronounced influence on the
NF-jB p65 transcriptional activity but does not influence NF-jB
Fig. 7. RGFP966 does not affect the localization of HDAC 3 and HDAC 3 – NF-jB p65 interaction in LPS/IFNc-stimulated RAW 264.7 macrophages. After 20 h incubation with
RGFP966 followed by 1 h LPS/IFNc stimulation, RAW 264.7 macrophages were prepared for immunofluorescence microscopy (A). The green signal represents NF-kB p65
protein, while the blue signal visualizes the Hoechst-stained nuclei. RGFP966 did not affect the nuclear localization of HDACs 1–3 compared to (vehicle-treated) control
group. The presented data set shows representative images of 4 independent experiments. Images of the cells were taken using confocal laser scanning microscopy and all
images were taken with identical instrumental conditions, original magnification 630. In addition, the effect of RGFP966 on HDAC 1–3 localization in LPS/IFNc-stimulated
RAW 264.7 macrophages was analyzed by immunoblotting cell fractions (data not shown) and quantified by densitometric analysis (B). PARP-1 and b-actin were used as
internal controls. Control (vehicle-treated) cells were set at 100%. Data are presented as mean values ± SD of 3–4 independent experiments. The HDAC 3 – NF-jB p65
interaction in LPS/IFNc-stimulated RGFP966-treated RAW 264.7 macrophages was investigated by immunoprecipitation of NF-jB p65 followed by immunoblotting for HDAC
3, which was quantified by densitometric analysis (C). Protein levels were normalized against NF-jB p65. Data are presented as mean values ± SD of 3 independent
experiments and a representative blot is shown. *p < 0.05 compared to vehicle. (For interpretation of the references to color in this figure legend, the reader is referred to the
web version of this article.)
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nism of action of HDAC 3 inhibition. In addition, no changes in glo-
bal histone H3 and H4 acetylation levels were detected. Taken
together these data indicate that pharmacological HDAC 3 inhibi-
tion in RAW 264.7 macrophages inhibits NF-jB p65 transcriptional
activity via a mechanism in which the HDAC 3 enzymatic activity
plays a key role.
In summary, the results of our study demonstrate that selective
pharmacological inhibition of HDAC 3 using RGFP966 has
anti-inflammatory effects in response to LPS/IFNc in RAW 264.7
macrophages and ex vivo in mouse PCLS. Moreover, RGFP966 sig-
nificantly reduced the transcriptional activity of NF-jB p65,
whereas NF-jB p65 acetylation and localization remain unaltered.
Our observations confirm the pro-inflammatory role of HDAC 3 in
macrophages, and demonstrate for the first time that HDAC
3-selective inhibition in mouse PCLS (a model for inflammatory
lung disease) attenuates inflammatory responses. The findings pre-
sented in this study justify further optimization and investigation
of pharmacological HDAC 3-selective inhibitors such as RGFP966
with the perspective toward development of anti-inflammatory
drugs for application in inflammatory lung diseases.
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